Healthcare
Anbc, Inc.(SYUP)
Live Price
Offline$0.0002
+0.00% today
Window Change
+0.00%
Window
May 27, 2026 → Jun 17, 2026
- Market Cap
- —
- Revenue Growth
- +10.0%
- EPS Growth
- -70.9%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars · May 27, 2026 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Anbc, Inc. (SYUP) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (May 27, 2026 → Jun 17, 2026). Baseline metrics include revenue growth of +10.0%, EPS growth of -70.9%, a dividend yield of 0.0%. What stands out right now is revenue +10.0%, EPS -70.9%, free cash flow +12035.0% with operating margin 42.8% and ROIC 70.4%. Valuation is more restrained than many high-expectation growth names at P/E 0.0 and price/sales 0.0. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines SYUP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.0% vs +7.6% peer median
Operating Margin
Above sector median
+42.8% vs +19.4% peer median
P/E
Below sector median
0.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at +10.0% and EPS is at -70.9%, with operating margin around 42.8%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYUP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYUP Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SYUP and SPY.
Company Overview
Anbc, Inc.
Other OTC
Shanghai Yutong Pharma, Inc. engages in the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals in the People's Republic of China. Its products primarily include Qilisheng a product formulated to be a general health enhancer by fortifying the immune system; Qi-ju-di-huang, an oral solution that protects the kidney and the liver; Qing-re-jie-du, an oral solution that reduces fever and relieves heat; Sheng-mai-yin, a solution that protects energy and enhances body fluids; Xiao-qing-long, an oral solution that relieves cough and dyspnea; Shen-bao, a syrup for the treatment of impotence and spermatorrhoea; Ban-xia, a syrup that relieves cough; and Gan-mao-zhi-ke, a syrup that relieves flu symptoms, cough, and nasal congestion. It also offers Ban-lan-gen that relieves cold and flu symptoms; Gan-mao-qing-re that relieves minor body aches and pains, and reduces fever; Huang-dan-yin-chen used in the treatment for jaundice infection hepatitis; and Liu-shen-qu for treatment of vomitings and dysentery. It offers its products to distributors on a wholesale basis. The company is based in Shanghai, China.
- Leadership
- Wei Dong
- IPO Date
- Jul 24, 2009
- Street Address
- No 2020 Huqingping Road
- Mailing
- Shanghai, 201702
- Region
- Shanghai, CN
- Reporting Currency
- USD
- Investor Line
- 86 21 5976 0042
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 0.0
- EV/EBITDA
- —
- Price/Sales
- 0.0
- Price/Book
- 0.0
Growth
- Revenue
- +10.0%
- EPS
- -70.9%
- Free Cash Flow
- +12035.0%
Profitability
- Gross Margin
- 49.1%
- Operating Margin
- 42.8%
- Net Margin
- 41.1%
- ROE
- 86.0%
- ROIC
- 70.4%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 2.75
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.